A post-hoc analysis of the THAOS registry (Transthyretin Amyloidosis Outcomes survey) was conducted with data from 1,441 patients who had ATTR-CM and a predominantly cardiac phenotype. Patients were categorised as tafamidis-treated if they received tafamidis while enrolled in THAOS or tafamidis-untreated if they have never received tafamidis while enrolled in THAOS. The analysis included all patients in the registry with a predominately cardiac phenotype at enrolment, defined as patients with ATTR-CM without signs and symptoms suggestive of associated ATTR amyloidosis- related neuropathy.

The post-hoc analysis included patients who received any dosage of tafamidis, not just the licensed tafamidis meglumine 80 mg daily/tafamidis 61 mg daily, to provide real-world representation beyond the scope of randomised clinical trials.¹

The results presented below on this page will only focus on patients who received tafamidis meglumine 80 mg daily/tafamidis 61 mg daily

Adapted from: Garcia-Pavia P et al. J Card Fail 2024; S1071-9164(24)00222-7

• This study was an observational registry in which data are not always complete, and baseline data were not available for all patients; most of the data came from US study sites from patients with a predominantly cardiac phenotype
• Propensity-matched analyses were not possible, given the amount of incomplete data
• The observational nature of this study had the potential to introduce selection bias, ascertainment bias, or temporal‡ bias
• Median follow-up time was 2 years in both groups, limiting the reliability of the survival analyses in later months
• The small number of patients with variant TTR genotypes prevents robust conclusions regarding survival in these subgroups
• Data on the use of SPECT imaging used in patients diagnosed with scintigraphy are not available, so misdiagnosis is possible as cardiac scintigraphy in the absence of SPECT can lead to false positives

References: